Laigo Bio

Laigo Bio BV specializes in innovative therapeutic solutions, particularly in oncology. The company was founded in Utrecht, Netherlands. Laigo Bio specializes in targeted protein degradation through its proprietary technology platform known as SureTACs (Surface Removal Targeting Chimeras). The core product offering involves the development of bispecific antibodies that facilitate the precise removal of disease-causing proteins from cell surfaces, particularly in oncology and autoimmune diseases. By leveraging an understanding of E3 ligase function, Laigo Bio creates selective therapies that target undruggable proteins, enhancing tumor-tissue specificity and improving therapeutic outcomes. The company's innovative approach is aimed at addressing unmet needs in cancer treatment and expanding into other therapeutic areas, such as immunology and neuroinflammation. The company’s revenue model is based on strategic partnerships, where it collaborates with large pharmaceutical firms for the clinical advancement of its novel therapies. These partnerships often involve milestone payments and royalties based on the commercial success of the developed therapies. Given the focus on precision medicine, Laigo Bio's transactions are likely to center on licensing agreements and collaborative research initiatives, allowing it to monetize its proprietary technologies as they progress through clinical trials and into market-ready products. The emphasis on first-in-class therapies positions Laigo Bio to generate revenue streams through both direct B2B transactions and potential future product sales following successful commercialization.

1. Seed

   Mar 23, 2026

   Amount

   $6.4M

   Investors

   Locked

2. Seed

   Dec 4, 2025

   Amount

   $13M

   Investors

   Locked